A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Purpose
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of etentamig, followed by a dose expansion phase to confirm the dose. Approximately 320 adult participants with R/R MM will be enrolled in the study in approximately 48 sites worldwide. Participants will receive intravenous (IV) etentamig co-administered with oral/IV Pd, oral/IV Rd, or oral/IV/subcutaneous (SC) Dd in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Condition
- Relapsed/Refractory Multiple Myeloma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Eastern Cooperative Oncology Group (ECOG) performance of <= 2. - Must have confirmed diagnosis of Relapsed/Refractory (R/R) Multiple Myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) criteria. - Must have measurable disease as determined by central lab as outlined in the protocol. - Must be naïve to treatment with Etentamig. - Must have never received BCMA-targeted therapy. Participants who have received targeted therapy against non-BCMA targets will not be excluded. - Arms A, B and C: Participant has received at least 3 prior lines of MM treatment. - Arm E: Participant has received 1-3 prior lines of MM treatment.
Exclusion Criteria
- Received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study treatment. - Unresolved adverse event (AE)s >= Grade 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) from prior anticancer therapy. - Has any of the following conditions: - Nonsecretory Multiple Myeloma (MM). - Active Plasma cell leukemia i.e., either 20% of peripheral white blood cells or > 2.0 × 10^9L circulating plasma cells by standard differential. - Waldenstrom's macroglobulinemia. - Light chain amyloidosis. - Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome. - Major surgery within 4 weeks prior to first dose or planned study participation. - Acute infections within 14 days prior to first dose of study requiring therapy (antibiotic, antifungal or antiviral). - Uncontrolled diabetes or hypertension within 14 days prior to first dose. - Peripheral neuropathy >= Grade 3 or >= Grade 2 with pain within 2 weeks prior to first dose.
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Part 1: Arm A (Etentamig with Pomalidomide and Dexamethasone) |
Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive etentamig with Pomalidomide and Dexamethasone. |
|
|
Experimental Part 1: Arm B (Etentamig with Lenalidomide and Dexamethasone) |
Participants with R/R MM who meet the criteria outline in the protocol will receive etentamig with Lenalidomide and Dexamethasone. |
|
|
Experimental Part 1: Arm C (Etentamig with Daratumumab and Dexamethasone) |
Participants with R/R MM who meet the criteria outline in the protocol will receive etentamig with Daratumumab and Dexamethasone. |
|
|
Experimental Part 2: Arm E (Etentamig with Pomalidomide and Dexamethasone) |
Participants with R/R MM who meet the criteria outline in the protocol will receive etentamig with Pomalidomide and Dexamethasone, after 1-3 prior lines of therapy. |
|
Recruiting Locations
Little Rock 4119403, Arkansas 4099753 72205
Miami 4164138, Florida 4155751 33136-1002
Tampa 4174757, Florida 4155751 33612-9416
Boston 4930956, Massachusetts 6254926 02215
Site Coordinator
(617) 632-3000
Worcester 4956184, Massachusetts 6254926 01655
Ann Arbor 4984247, Michigan 5001836 48109
Paramus 5102387, New Jersey 5101760 07652
New York 5128581, New York 5128638 10029-6030
New York 5128581, New York 5128638 10065-6007
Charlotte 4460243, North Carolina 4482348 28204
Dallas 4684888, Texas 4736286 75390-7208
Site Coordinator
214-648-3111
Salt Lake City 5780993, Utah 5549030 84112-5500
Seattle 5809844, Washington 5815135 98109
Milwaukee 5263045, Wisconsin 5279468 53226-3522
More Details
- NCT ID
- NCT05259839
- Status
- Recruiting
- Sponsor
- AbbVie